In prostate cancer, it has been described that a combination of melatonin (orally at 20 mg/day, in the evening every day until progression, starting 7 days prior to triptorelin) and the LHRH analogue triptorelin may overcome the resistance to LHRH analogues and palliate the adverse side effects [74]. The gene discussed is GNRH1; the disease is Familial prostate cancer.